Refining functional phenotypes in an international cohort of untreated paediatric type 2 and 3 SMA patients using the Revised Hammersmith Scale
Year: 2026
Type: article
Study design: Observational Study
Abstract: Spinal muscular atrophy types 2 and 3 encompass a wide spectrum of motor abilities ranging from non-sitting to sitting and walking. This study refines a functional group termed high functioning sitter-standers, positioned between traditional categories, and examined in relation to both the Revised Hammersmith Scale and a World Health Organization motor milestone-based framework. Among 178 participants completing 618 assessments, 109 were classified as type 2, 59 as type 3a, and 10 as type 3b, with ages ranging from 1 to 17.5 years. Twenty-seven non-sitters completed 54 assessments, 110 sitters completed 347, and 50 walkers completed 169, while the high functioning sitter-standers accounted for 48 assessments of 21 individuals. This newly defined group scored significantly lower than walkers and higher than both sitters and non-sitters, highlighting a distinct and measurable functional profile. Although no significant differences in age distribution were observed between the high functioning sitter-standers and walkers or non-sitters, sitters were notably younger. This intermediate phenotype captures patients with partial standing and assisted walking abilities, often overlooked in previous analyses. Recognition of this group is important for understanding emerging functional trajectories in treated spinal muscular atrophy and for informing future outcome measures and quality of life assessments.
Source: Neuromuscular Disorders
Institutions: Great Ormond Street Hospital, National Institute for Health and Care Research, NIHR Great Ormond Street Hospital Biomedical Research Centre, University College London, University of Suffolk, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle University, Università Cattolica del Sacro Cuore, Columbia University Irving Medical Center, Children's Hospital of Philadelphia, Boston Children's Hospital, Stanford University, University of Central Florida, St. Jude Children's Research Hospital, Agostino Gemelli University Polyclinic, UCL Biomedical Research Centre
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,470
Funders: Pfizer, Sanofi, Muscular Dystrophy Association, Biogen, Parent Project Muscular Dystrophy, Children's Hospital of Philadelphia, F. Hoffmann-La Roche, Cure SMA, Duchenne Research Fund, Sarepta Therapeutics, Amicus Therapeutics, Argenx, Insmed, Astellas Pharma, Italfarmaco, Genentech, National Institute of Child Health and Human Development
OpenAlex ID: W7127350373
